MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: HER2-low

HER2-low

Latest news

Tag

news

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat

Jan 13, 2026
Hematology-Oncology

DESTINY-Breast04 Consolidated: Trastuzumab Deruxtecan Improves Survival and Maintains Quality of Life in HER2‑Low Metastatic Breast Cancer

DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte

Nov 12, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story